NCT06361927
A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- NSCLC
- Drug/Device/Intervention
- SSGJ-707
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Location
- Changsha, China
Timeline & enrollment
- Phase
- Phase 2
- Start date
- May 15, 2024
- End date
- Jul 01, 2025
- Enrollment
- 120 participants
Primary outcome
ORR
Summary
This study includes two cohorts, cohort A is for non-squamous NSCLC and cohort B is for
 squamous NSCLC.
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06361927
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06361927 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.